A Phase 3 interventional study of Selexipag in Pulmonary Arterial Hypertension, sponsored by Actelion. Completed at 15 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-01-23.
Sponsored by Actelion (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing selexipag in Pulmonary Arterial Hypertension — 1 open to participants now, 3 under way, 1 of them phase 3. selexipag · Pulmonary Arterial Hypertension.
Among the 12 studies testing selexipag in Pulmonary Arterial Hypertension, this one is the 8th largest by enrollment, is the only one that started in 2015, is one of 6 in phase 3, and was the 3rd registered.
700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.
Browse Pulmonary Arterial Hypertension studies →1 of the 12 studies testing selexipag in Pulmonary Arterial Hypertension is open now, in 12 countries. Recruiting first, the newest first:
Actelion · Sites in Belarus, Belgium, Bulgaria and 10 more countries
Ages 2+
By country, each count listing its studies:
selexipag: first FDA approval 2015 (UPTRAVI), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 34 is below the median of 40 across 478 interventional studies indexed under Pulmonary Arterial Hypertension.
Median enrollment 67 across the 12 interventional studies. Of the 8 that completed or were terminated, 7 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 12 have an industry lead sponsor. The 4 most frequent:
This study is registered under Actelion, one of the names counted as Johnson & Johnson. Under that name alone:
Actelion is the lead sponsor of 143 studies on the registry; 1 is open to participants now.
Of its 28 completed or terminated interventional studies of FDA-regulated products, 25 (89%) have results posted.
63 studies in Pulmonary Arterial Hypertension by Johnson & Johnson: 2 open now, 5 under way, 2 of them phase 3. Of 55 finished, 33 (60%) have results posted.
Among the 63 studies in Pulmonary Arterial Hypertension by Johnson & Johnson, this one is the 40th largest by enrollment of the 51 interventional ones that give a count, is one of 4 that started in 2015, is one of 31 in phase 3, and was the 43rd registered.
Johnson & Johnson’s Pulmonary Arterial Hypertension studies by the year they started, since 2003.
1 of the studies testing selexipag in Pulmonary Arterial Hypertension that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05179876Phase 3ActelionA Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option | 2027-01-31 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing selexipag in Pulmonary Arterial Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Johnson & Johnson’s 63 in Pulmonary Arterial Hypertension:
This tab as a report to print or save as PDF → With an account.
This study enrolls patients with pulmonary arterial hypertension (PAH) treated with inhaled treprostinil. During the study, the treatment with inhaled treprostinil will be tapered off and simultaneously replaced with an oral treatment (selexipag) targeting the disease in a similar way. The purpose of the study is i) to investigate the safety and tolerability of oral selexipag in patients who transition from inhaled treprostinil, ii) to investigate the effects of oral selexipag on PAH severity and exercise ability before and after transition, and iii) to gain new information about the patients experience taking oral selexipag compared to inhaled treprostinil. Study participants may stay in the study until the FDA has granted marketing authorization.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects on inhaled treprostinil treatment participate in a 16-week main treatment period including down-titration of treprostinil to end of Week 8 and parallel up-titration of selexipag to the maximum tolerated dose (MTD) up to Week 12, for each individual patient but not above 1600 mcg twice daily. From Week 12 up to Week 16, patients continue selexipag at their individual MTD. Patients could continue the study drug selexipag during the extended treatment period from Week 16 until commercial availability of selexipag.
Drug: Selexipag
Tablets for oral administration containing 200 micrograms (mcg) of selexipag to be administered twice a day. The individual dose is to be established during the first 12 weeks of the study. Doses are in the range from 200 micrograms (1 tablet) to 1,600 micrograms (8 tablets).
Also known as: Uptravi, ACT-293987
Percentage of Subjects With Sustained Treatment Transition
A sustained treatment transition is considered if the 3 following criteria are met a) being on study treatment (selexipag) at Week 16, and b) not having a study treatment interruption(s) of a total of 8 days or more prior to Week 16, and c) absence of inhaled treprostinil or any prostanoid treatment after Week 8 up to Week 16. The percentage of subjects with a sustained treatment transition is calculated with 95% confidence interval (CI) using the Clopper-Pearson method.
Time frame: At Week 16
Percentage of Subjects With Treatment-emergent Adverse Events (AEs),
Percentage of subjects with treatment-emergent AEs (serious and non serious), regardless of relationship to selexipag
Time frame: 26 weeks on average (from the first dose of selexipag up to 30 days after the last dose of selexipag)
Number of Subjects With Adverse Events Leading to Premature Discontinuation of Selexipag
Number of subjects with adverse events leading to premature discontinuation of selexipag is determined from the first dose of selexipag up to the last dose of selexipag
Time frame: Up to 22 weeks on average
Absolute Change From Baseline Over Time in Blood Pressure
Both systolic(SBP) and diastolic (DBP) arterial blood pressure were measured in a sitting position after at least 5 minutes of rest at scheduled time points. Median change from baseline to pre-specified post-baseline visits are calculated
Time frame: Baseline, Week 4, Week 12, Week 16
Absolute Change From Baseline Over Time in Heart Rate (HR)
Pulse rate is measured after at least 5 minutes of rest in a sitting position. Median change from baseline to pre-specified post-baseline visits are calculated.
Time frame: Baseline, Week 4, Week 12, Week 16
Maximal Tolerated Dose
This is the individual maximal tolerated dose (MTD) observed at Week 12 in the subjects still on selexipag at Week 16. MTD is defined as the dose of selexipag reached with the last dose change up to Week 12
Time frame: At Week 12, in subjects still on selexipag at Week 16
Time to Discontinuation of Inhaled Treprostinil.
Median time from baseline (Day1) to the end of down-titration of inhaled treprostinil is calculated
Time frame: Baseline to Week 16
Percentage of Subjects With WHO Functional Class (FC) Change From Baseline
The World Health Organization (WHO) defines 4 classes to classify the functional status of patients with pulmonary hypertension: Class I (FC I): No limitation of physical activity. Class II (FC II): Slight limitation of physical activity. Class III (FC III): Marked limitation of physical activity. Class IV (FC IV): Inability to carry out any physical activity without symptoms. Number of patients with improvement (shift from a higher to a lower class), worsening (shift from a lower to a higher class) or no change in WHO functional class at end of study compared to baseline are determined.
Time frame: Baseline and Week 16
Absolute Change in 6-minute Walk Distance (6MWD) at Trough
The 6MWT is a non-encouraged test, which measures the distance (in meters) covered by the subject during a 6-minute walk. It is performed in a 30-meters long flat corridor, where the patient is instructed to walk as far as possible, back and forth around two cones, with the permission to slow down, rest, or stop if needed. Absolute change from baseline to Week 16 in 6MWD is measured at trough levels of inhaled treprostinil and/or selexipag. The trough level of inhaled treprostinil is defined as the last dose having been taken not less than 4 hours and not more than 48 hours prior to the 6MWT at Visit 1 (screening). The trough level of selexipag was defined as the last dose having been taken not less than 8 hours and not more than 7 days prior to the 6MWT at Visit 5 (Week 16).
Time frame: Baseline and Week 16
Percentage of Patients With Change in 6-minute Walk Distance (6MWD)
Percentage of patients with an increase (\> 8% of baseline), maintenance (+/- 8% of baseline), or decrease (\< -8% of baseline) in their 6MWD (at trough) from baseline to Week 16. The ± 8% boundaries for change in 6MWD reflect the approximately 8% coefficient of variation in the reproducibility of the 6MWD. The trough level of inhaled treprostinil is defined as the last dose having been taken not less than 4 hours and not more than 48 hours prior to the 6MWD test at Visit 1 (screening). The trough level of selexipag was defined as the last dose having been taken not less than 8 hours and not more than 7 days prior to the 6MWD test at Visit 5 (Week 16).
Time frame: Baseline and Week 16
Geometric Mean of the Ratio in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP) of Week 16 to Baseline
Changes in NT-proBNP levels in plasma are expressed by the geometric mean of the ratio of Week 16 to baseline
Time frame: Baseline and Week 16
Change From Baseline to Week 16 in the Treatment Satisfaction Questionnaire for Medication Questionnaire (TSQM II)
The Treatment Satisfaction Questionnaire for Medication, Version II (TSQM II) is a validated tool that evaluate the subject's satisfaction with the study treatment. It includes a total of 11 questions related to satisfaction with treatment effectiveness, side effects,convenience, and global satisfaction. TSQM scores range from 0 to 100 for each domain; a higher score indicates higher satisfaction with treatment.
Time frame: Baseline and Week 16
Thirty-seven patients were screened. Among them, thirty-four patients with pulmonary arterial hypertension (PAH) and treated with inhaled treprostinil for at least 90 days were enrolled at 12 sites in the USA.
| Milestone | Selexipag |
|---|---|
| Started | 34 |
| Completed | 32 |
| Not completed | 2 |
| Withdrew: Adverse event | 1 |
| Withdrew: Withdrawal by subject | 1 |
| Milestone | Selexipag |
|---|---|
| Started | 32 |
| Completed | 31 |
| Not completed | 1 |
| Withdrew: Lack of efficacy | 1 |
A sustained treatment transition is considered if the 3 following criteria are met a) being on study treatment (selexipag) at Week 16, and b) not having a study treatment interruption(s) of a total of 8 days or more prior to Week 16, and c) absence of inhaled treprostinil or any prostanoid treatment after Week 8 up to Week 16. The percentage of subjects with a sustained treatment transition is calculated with 95% confidence interval (CI) using the Clopper-Pearson method.
| Percentage of participants | Selexipag |
|---|---|
| Percentage of Subjects With Sustained Treatment Transition | 82.4 (65.5 to 93.2) |
Percentage of subjects with treatment-emergent AEs (serious and non serious), regardless of relationship to selexipag
| Percentage of participants | Selexipag |
|---|---|
| Percentage of Subjects With Treatment-emergent Adverse Events (AEs), | 97.1 |
Number of subjects with adverse events leading to premature discontinuation of selexipag is determined from the first dose of selexipag up to the last dose of selexipag
| Participants | Selexipag |
|---|---|
| Number of Subjects With Adverse Events Leading to Premature Discontinuation of Selexipag | 3 |
Both systolic(SBP) and diastolic (DBP) arterial blood pressure were measured in a sitting position after at least 5 minutes of rest at scheduled time points. Median change from baseline to pre-specified post-baseline visits are calculated
| mmHg | Selexipag |
|---|---|
| SBP change from baseline at week 4 | 1.00 (-32.0 to 59.0) |
| SBP change from baseline at week 12 | -3.00 (-28.0 to 35.0) |
| SBP change from baseline at week 16 | -4.00 (-24.0 to 25.0) |
| DBP change from baseline at week 4 | -3.00 (-26.0 to 34.0) |
| DBP change from baseline at week 12 | -4.00 (-30.0 to 48.0) |
| DBP change from baseline at week 16 | -6.00 (-21.0 to 15.0) |
Pulse rate is measured after at least 5 minutes of rest in a sitting position. Median change from baseline to pre-specified post-baseline visits are calculated.
| beats per minute (bpm) | Selexipag |
|---|---|
| HR change from baseline at week 4 | 4.00 (-23.0 to 22.0) |
| HR change from baseline at week 12 | 6.00 (-34.0 to 33.0) |
| HR change from baseline at week 16 | 3.00 (-35.0 to 23.0) |
This is the individual maximal tolerated dose (MTD) observed at Week 12 in the subjects still on selexipag at Week 16. MTD is defined as the dose of selexipag reached with the last dose change up to Week 12
| mcg | Selexipag |
|---|---|
| Maximal Tolerated Dose | 1200 (400 to 1600) |
Median time from baseline (Day1) to the end of down-titration of inhaled treprostinil is calculated
| weeks | Selexipag |
|---|---|
| Time to Discontinuation of Inhaled Treprostinil. | 6.21 (1.0 to 14.9) |
The World Health Organization (WHO) defines 4 classes to classify the functional status of patients with pulmonary hypertension: Class I (FC I): No limitation of physical activity. Class II (FC II): Slight limitation of physical activity. Class III (FC III): Marked limitation of physical activity. Class IV (FC IV): Inability to carry out any physical activity without symptoms. Number of patients with improvement (shift from a higher to a lower class), worsening (shift from a lower to a higher class) or no change in WHO functional class at end of study compared to baseline are determined.
| percentage of participants | Selexipag |
|---|---|
| % subjects with WHO FC improvement | 26.5 |
| % subjects with WHO FC worsening | 5.9 |
| % subjects with WHO FC unchanged | 67.6 |
The 6MWT is a non-encouraged test, which measures the distance (in meters) covered by the subject during a 6-minute walk. It is performed in a 30-meters long flat corridor, where the patient is instructed to walk as far as possible, back and forth around two cones, with the permission to slow down, rest, or stop if needed. Absolute change from baseline to Week 16 in 6MWD is measured at trough levels of inhaled treprostinil and/or selexipag. The trough level of inhaled treprostinil is defined as the last dose having been taken not less than 4 hours and not more than 48 hours prior to the 6MWT at Visit 1 (screening). The trough level of selexipag was defined as the last dose having been taken not less than 8 hours and not more than 7 days prior to the 6MWT at Visit 5 (Week 16).
| meters | Selexipag |
|---|---|
| Absolute Change in 6-minute Walk Distance (6MWD) at Trough | -10.25 (-25.60 to 8.80) |
Percentage of patients with an increase (\> 8% of baseline), maintenance (+/- 8% of baseline), or decrease (\< -8% of baseline) in their 6MWD (at trough) from baseline to Week 16. The ± 8% boundaries for change in 6MWD reflect the approximately 8% coefficient of variation in the reproducibility of the 6MWD. The trough level of inhaled treprostinil is defined as the last dose having been taken not less than 4 hours and not more than 48 hours prior to the 6MWD test at Visit 1 (screening). The trough level of selexipag was defined as the last dose having been taken not less than 8 hours and not more than 7 days prior to the 6MWD test at Visit 5 (Week 16).
| Percentage of participants | Selexipag |
|---|---|
| 6MWD decreased | 26.5 |
| 6MWD maintained | 55.9 |
| 6MWD increased | 17.6 |
Changes in NT-proBNP levels in plasma are expressed by the geometric mean of the ratio of Week 16 to baseline
| Geometric mean of the ratio | Selexipag |
|---|---|
| Geometric Mean of the Ratio in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP) of Week 16 to Baseline | 1.1 (0.82 to 1.62) |
The Treatment Satisfaction Questionnaire for Medication, Version II (TSQM II) is a validated tool that evaluate the subject's satisfaction with the study treatment. It includes a total of 11 questions related to satisfaction with treatment effectiveness, side effects,convenience, and global satisfaction. TSQM scores range from 0 to 100 for each domain; a higher score indicates higher satisfaction with treatment.
| Units on a scale | Selexipag |
|---|---|
| Effectiveness (change from baseline) | 0.00 (-8.3 to 8.3) |
| Side effects (change from baseline) | 0.00 (-16.7 to 0.0) |
| Convenience (change from baseline) | 44.44 (27.8 to 61.1) |
| Global satisfaction (change from baseline) | 8.33 (0.0 to 25.0) |
Collected over From study treatment initiation up to 30 days after study treatment discontinuation. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Selexipag | 0/34 (0%) | 2/34 (5.9%) | 33/34 (97.1%) |
| Event | Selexipag |
|---|---|
| Generalised tonic-clonic seizureNervous system disorders | 1/34 |
| Muscle haemorrhageMusculoskeletal and connective tissue disorders | 1/34 |
| NauseaGastrointestinal disorders | 1/34 |
| SyncopeNervous system disorders | 1/34 |
| VomitingGastrointestinal disorders | 1/34 |
| Event | Selexipag |
|---|---|
| HeadacheNervous system disorders | 27/34 |
| DiarrhoeaGastrointestinal disorders | 24/34 |
| Pain in jawMusculoskeletal and connective tissue disorders | 16/34 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 11/34 |
| MyalgiaMusculoskeletal and connective tissue disorders | 9/34 |
| FatigueGeneral disorders | 8/34 |
| FlushingVascular disorders | 8/34 |
| DizzinessNervous system disorders | 7/34 |
| NauseaGastrointestinal disorders | 7/34 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 7/34 |
| Age, Customized(Participants) | Selexipag |
|---|---|
| Age categories as per protocol — <= 65 years | 28 |
| Age categories as per protocol — >65 years and <75 years | 5 |
| Age categories as per protocol — >= 75 years | 1 |
| Sex: Female, Male(Participants) | Selexipag |
|---|---|
| Female | 28 |
| Male | 6 |
| Race/Ethnicity, Customized(Participants) | Selexipag |
|---|---|
| Race categories as per protocol — Black or African American | 2 |
| Race categories as per protocol — Asian | 3 |
| Race categories as per protocol — White | 28 |
| Race categories as per protocol — Other | 1 |
| Etiology of pulmonary arterial hypertension (PAH)(Participants) | Selexipag |
|---|---|
| Idiopathic | 19 |
| Heritable | 0 |
| Drug or toxin induced | 5 |
| Associated PAH | 10 |
| World Health Organization Functional class (WHO FC)(Participants) | Selexipag |
|---|---|
| FC I | 0 |
| FC II | 25 |
| FC III | 9 |
| FC IV | 0 |
| Time since initial inhaled treprostinil(Months) | Selexipag |
|---|---|
| Median | 37.8 (4.4 to 135.2) |
| Treprostinil stable dose(Participants) | Selexipag |
|---|---|
| < 54 mcg q.i.d. | 2 |
| 54 mcg q.i.d. | 20 |
| > 54 mcg q.i.d. | 12 |
| PAH-specific therapy at baseline(Participants) | Selexipag |
|---|---|
| PDE5-inhibitors alone | 7 |
| ERAs alone | 4 |
| ERAs and PDE-5 | 19 |
| ERAs and sCG stimulator | 4 |
Ran from Oct 2015 to primary completion in Dec 2016, 13 months.
Results were first posted in Dec 2017, 1 year after primary completion.
Of 43 industry-sponsored phase 3 interventional studies under Pulmonary Arterial Hypertension, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 83. This study's 13 months is below that.
Counting every sponsor, half of 49 studies reached it within 50 months; a quarter within 31 and three quarters within 83.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Selexipag
Pulmonary Arterial Hypertension →